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Desfiurane, a newly introduced potent, inhaled anesthetic, differs from its pre-
decessors in having alower solubility inblood and tissues. The lower solubility
imparts a greater control to the maintenance of anesthesia and a more rapid
elimination and recovery from anesthesia. In other respects, the pharmaco-
logical properties of desflurane resemble those of its sister anesthetic, isoflu-
rane, currently the most widely-used potent anesthetic in this and other coun-
tries. The qualitative exceptions to this resemblence are that desfiurane is more
pungent and produces a greater increase in heart rate, particularly at deeper
levels ofanesthesia.
The drugs developed for anesthetic purposes in the past decade have focused on the
perceived need for a greater control over the anesthetic state, including a need to provide
a more rapid recovery from anesthesia. Thus, midazolam has replaced diazepam, propo-
fol is used instead ofthiopental, and atracurium and vecuronium have displaced pancuro-
nium. On the horizon beyond these advances are injected drugs with even shorter dura-
tions of action, affording even greater control over the anesthetic state. The delivery of
inhaled anesthetics may similarly change. Desflurane, recently introduced to clinical
practice in the United States, provides a greater control over the maintenance ofanesthe-
sia, and a more rapid recovery from anesthesia than previously available inhaled anes-
thetics.
The mechanisms supplying greater control and more rapid recovery differ among the
classes ofanesthetic drugs. To achieve these ends, injected drugs depend on a more rapid
rate ofmetabolism, a more limited volume ofdistribution, and/or a more rapid redistribu-
tion. Modem inhaled anesthetics rely on the last two ofthese means, and both resultfrom
lower blood/gas and tissue/blood partition coefficients. Inhaled anesthetic differ from
injected agents in the obvious routes of injection and elimination, routes that confir spe-
cial advantages to the inhaled approach to anesthesia, perhaps particularly to the newer,
less soluble inhaled anesthetics. First, elimination via the lungs is always assured and
subject to but minimal variation fora given agent. Second, the lungs provide a window to
the effective partial pressures imposed on the patient: we can know with precision these
partial pressures, either with devices that measure anesthetic concentrations or, in the case
ofless soluble agents, by theconcentration produced by the vaporizer.
Molecular structure andphysical characteristics
A lower solubility in blood and tissues is accomplished by halogenation solely with
fluorine [1]. Indeed, desflurane is distinguished from its predecessor, isoflurane, by the
substitution ofasingle fluorine forachlorine on the a-ethyl moiety (Table 1). Before dis-
cussing solubility and its impact on kinetics, we will consider the impact of fluorination
vs. chlorination on some other physical properties. Fluorination changes boiling point,
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Table 1. Physical properties ofsome potentmodern Inhaled anesthetics [7].
Name Desflurane Sevoflurane Isoflurane Halothane
Structure CHF20CHFCF3 CH2FOCH(CF3)2 CHF20CHCICF3 CF3CHCIBr
Gram Molecular 168 200 184.5 197
Weight
Specific Gravity 1.47 1.50 1.50 1.86
(g/mL)
Vapor Pressure 669 160 240 244
(20°C) (mm Hg)
Blood/Gas PartCoef. 0.45 0.65 1.4 2.5
MAC (30-60 years) 6.0 2.0% 1.15% 0.75%
vapor pressure, and stability. The boiling point ofdesflurane (22.8°C) is much lower than
that of isoflurane at 48.5°C. Because the boiling point of desflurane is close to room
temperature, conventional plenum (tec-type) vaporizers cannot be used for this agent, and
a new vaporizer technology has been developed to permit the administration of desflur-
ane in a manner similar to that familiar to anesthetists using anesthetics such as isoflu-
rane. Thus, the concentration of desflurane delivered from the vaporizer is close to that
indicated on the dial, regardless ofroom temperature or thebackground gas flow rate,but
the manner in which this is accomplished differs from that used for isoflurane.
Fluorination also increases the stability ofthe molecule, increasing its resistance both
to biodegradation (to be considered later) and to breakdown by alkali, such as soda lime
or Baralyme. Desflurane is not measurably broken down by soda lime at temperatures of
40° - 60'C, and at 80°C, it is but slightly degraded [2]. In contrast, isoflurane is measur-
ably broken down at 60°C, and, at 80°C, the breakdown equals 12o/hr (Figure 1) [2].
Some anesthetics (e.g., sevoflurane) are broken down at far greater rates. Resistance to
breakdown may be desirable for two reasons. First, ifthe breakdown is sufficient, it may
be difficult to administer an adequate level of anesthesia using a low-flow (rebreathing)
system. Second, the breakdown products may be toxic, as is the case with the products
resulting from the degradation ofhalothane or sevoflurane [3]. The issue with such prod-
ucts is whether in clinical practice theconcentrations produced approach orare fardistant
from those thatcan cause injury [4].
Potency
Fluorination also affects potency. Desflurane is one-fifth as potent as is isoflurane
(respective MACC values for patients aged 30-60 years are 6.0% and 1.15%) [5 ,6].
Although desflurane is less potent than its sister compound, its MAC still permits the
administration ofhigh concentrations ofoxygen, even in thepresence ofnitrousoxide.
The MAC ofdesflurane is affected by the same factors thataffect the MAC ofother
potentanesthetics. MAC is decreased by increasing age (except for aslight increase from
the newborn to a few months oflife), by decreasing body temperature, and by the admin-
istration ofotherdepressant drugs such as nitrousoxide, fentanyl, and midazolam [7].
MAC-awake is the concentration at which 50% of patients or volunteers respond
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Figure 1. Anesthetics placed in a 581 mL sealed flask containing 100 gm of soda Ume may be
degraded and disappear. The degradation rate is a function of the anesthetic (sevoflurane >>
halothane = isoflurane > desflurane and the temperature at which the flask is held. (Reproduced
with permission from Eger [2])
appropriately to command, and for desflurane equals about 2.5% in subjects aged 20-30
years [8]. This is approximately one-third the value for MAC for this age group. MAC-
awake is important for two reasons. First, patients will not awaken after cessation of
anesthetic administration until the cerebral partial pressure decreases below that equivi-
lent to MAC-awake. Thus, the lower theratio ofMAC-awake to MAC, the longer will be
the time to recovery. Second, our studies suggest that MAC-awake is also the concentra-
tion (really, a partial pressure because the concentration for both MAC and MAC-awake
are defined as a percentage of one atmosphere) that abolishes memory [9]. Thus, desflu-
rane appears to be a potent amnestic anesthetic, one that is twice as potent in this regard
as nitrous oxide.
Uptake and distribution: implicationsfor induction and maintenance ofanesthesia and
for recoveryfrom anesthesia
The solubility ofdesflurane in blood is one-third that of isoflurane (blood/gas parti-
tion coefficients, respectively, 0.45 and 1.4), and the value for isoflurane is lower than
that for halothane (2.5). Desflurane also has lower lean tissue/blood partition coefficients
than either isoflurane or halothane [7]. As a consequence, the rate ofrise of the alveolar
concentration towards the concentration inspired is more rapid for desflurane than for
isoflurane which, in turn, has a more rapid rate ofrise than found with halothane (Figure
2) [10, 11]. One might be tempted to predict from this that apatient given the an inspired
concentration twice that ofthe MAC ofdesflurane would go to sleep morerapidly than if
given twice the MAC ofhalothane. This ignores another factor that influences the induc-
tion of anesthesia. Desflurane has a pungency that can cause breathholding, secretions,
coughing, and laryngospasm, particularly at inspired concentrations exceeding 6-7%,
whereas halothane has little or no pungency and does not evoke such respiratory respons-
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Figure 2. The alveolar anesthetic (FA) rate of rise toward the inspired concentration (F1) Is
largely determined by the solubility of the anesthetic, being more rapid with less soluble
agents such as nitrous oxide and desflurane than with a more soluble agent such as isoflurane.
(Modified from the dataofYasuda et al. [10])
es [7]. In adults, these irritant effects ofdesflurane do not produce respiratory responses
sufficient to lead to oxyhemoglobin desaturation. However, in children, desaturation can
occur anddesflurane is notrecommended for induction ofanesthesia in children.
Maintenance of anesthesia requires a control over the alveolar concentration, a
capacity to sustain a given level ofanesthesia and to rapidly increase ordecrease that lev-
el in response to changing surgical or patient needs. One measure of the control that can
be applied is the difference between the concentration of anesthetic delivered from the
vaporizer and the concentration it sustains in the alveoli. The smaller this difference, the
greater the control. Several factors affect this difference, including the degree of equili-
bration of tissues with anesthetic, but among the most important is solubility. Thus, the
ratio of the delivered concentration (FD) to the alveolar concentration that might be
desired (FA) will be considerably lower (the two values will be closer together) for des-
flurane than for isoflurane or halothane (Figure 3) [7]. The smaller ratio for desflurane
has several implications. One implication is the greater control defined above; a secondis
that the anesthetist can betterrely on the vaporizer setting to indicate thealveolar concen-
tration obtained in the patient, and a third is related to anesthetic cost, a point we will
return to later.
As would bepredicted from its lower solubility, theelimination ofdesflurane is more
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Figure 3. The data gathered by Yasuda et al. In volunteers may be used to predict the concen-
tration that must be delivered (FD) from a vaporizer to sustain a constant alveolar concentra-
tion (FA). The ratio of the two is inversely proportional to the uptake of the anesthetic. Thus, the
difference is greater early in anesthesia and smaller with less soluble anesthetics. At the end of an
hour ofanesthesia, FD must be only 10% greater than FA; whereas for isoflurane, a 60% difference
is found. The smaller difference for desflurane implies a greater, more predictable control over the
level ofanesthesia. A smaller difference also decreasescost. (Adapted from Eger [7])
rapid than the elimination of isoflurane or halothane (Figure 4) [10, 11]. These results
would suggest that awakening should be quicker with desflurane, and data from studies
in animals and humans confirm this suggestion. Patients given desfiurane respond to
commands about twice as rapidly as patients given isoflurane. This may add to the safety
of anesthesia in that a responsive patient may better support the airway. In addition to a
more rapid immediate recovery from anesthesia, longer-term recovery is more rapid
(Figure 5) [12, 13]. Results forboth subjective andobjective meaures ofrecovery suggest
thatpatients given desflurane return to normal approximately twice as rapidly as patients
given isoflurane. There may also be less shivering and delirium in patients given desflu-
rane, perhaps because they pass through the stages of disinhibition more rapidly [13].
These results suggest that patients given desflurane may be ready for discharge from the
post-anesthesia care unit sooner than patients given isoflurane. Although a few studies
support this view, others do not, and more definitive studies are needed to determine
whether this aspect ofdesflurane can lead to an earlier discharge, and potentially a lower
post-anesthesia care unitcost.
Respiratory effects
Apart from its greater pungency, the respiratory effects of desflurane are similar to
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Figure 4. Solubility influences the rate ofanesthetic elimination: a lower solubility accelerates
elimination. Thus, for desflurane the rate of decrease of the alveolar concentration of anesthetic
(FA) from the last alveolar anesthetic concentration obtained during anesthesia(FAO) easily outstrips
the rate ofdecrease found with isoflurane. (Adapted from Yasuda et al. [10])
those seen with isoflurane. Both compounds cause a dose-related increase in arterial
PCO2 and a decrease in the ventilatory response to imposed increases in pCO2 [14].
Desflurane has been used without difficulty in patients with a history of asthma [7], but
studies ofdesflurane's effect on bronchomotor tone remain to be done.
Circulatoryeffects
Desflurane and isoflurane similarly affect the circulation, differences between the
two being quantitative rather than qualitative. Neither anesthetic predisposes the heart to
the arrhythmogenic effect of epinephrine. Both decrease blood pressure by decreasing
systemic vascular resistance [15, 16]. Both tend to sustain cardiac output, at least in part
by providing sympathetic stimulation. Desflurane produces greater sympathetic stimula-
tion, and this stimulation becomes manifest at concentrations greater than 1 MAC [17].
The result of stimulation may be both a greater tendency to sustain cardiac output and
blood pressure, and a greater effect on heart rate. Thus, at concentrations above 1 MAC
(but not below 1 MAC), steady-state concentrations ofdesflurane produce a dose-related
increase in heart rate [15]. In addition, again at concentrations exceeding 1 MAC, abrupt
increases in the imposed concentration of desflurane can cause transient (2-4 min)
increases in heart rate and blood pressured. Such effects may underlie the transient
dWeiskoph and Eger, unpublished data.
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Figure 5. Recovery ofcoordination and cognitive function may occur more rapidly after anes-
thesia with desflurane than after anesthesia with a more soluble anesthetic such as Isoflurane.
Specifically, results for the digit symbol substitution test (a measure of cognition or judgment)
return to normal at about twice the speed withdesflurane. (Adapted fromTsai et al. [13])
ischemia seen by Helman et al. in 14% oftheirpatients during induction ofanesthesia for
coronary artery bypass procedures [18]. Such ischemia has not been seen by other inves-
tigators anesthetizing similar patients with desflurane but differing in their approach by
the useofopioids as amajorpartofthe induction process [19-21] (Helman etal. [18] did
not use opioids). The use of opioids may attenuate or abolish the sympathetic effects of
desflurane. Finally, desflurane does not appear to directly dilate coronary blood vessels
and does notproduce coronary steal in a conventional canine model which can be used to
reveal steal by coronary vasodilators such as adenosine [22].
Neuromuscular effects
Desflurane produces a dose-related impairment of myoneural transmission and can
be used to supply relaxation sufficient for any procedure [23]. Laryngoscopy can be
accomplished using the relaxation provided by desflurane. Like isoflurane, desflurane
enhances the effect of muscle relaxants. This confirs a theoretical safety to the use of
relaxants in thatwhen desflurane is eliminated theenhancing effectalso iseliminated.
Effects on the central nervoussystem
The electroencephalogram under anesthesia with desflurane resembles that found
during anesthesia with isoflurane [24]. Both agents cause an increase in low voltage-fast
waveactivity at low (sub-MAC) concentrations thatchanges tohighervoltage-slow wave
activity atanesthetizing levels with the appearance ofburstsuppression. Atdeep levels of
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anesthesia (> 1.5 MAC) the burst suppression may become continuous (isoelectric EEG).
Desflurane does not produce convulsive activity at any partial pressure or at any level of
pCO2.
Desflurane can cause cerebral vascular dilation, and cerebral blood flow increases if
blood pressure is sustained (e.g., by vasopressors) [25]. Cerebral responsiveness to
changes in pCO2 are maintained, even at anesthetizing concentrations ofdesflurane [26].
At concentrations up to about three-quarters of MAC, desflurane has little effect on
intracranial pressure, even in patients with intracranial space-occupying lesions [7].
Higher concentrations can increase intracranial pressures in such patients.
Malignant hyperthermia
No cases of malignant hyperthermia have been reported in humans. However, in a
swine model, desflurane cantriggermalignanthyperthermia [27].
Metabolism and toxicity
The substitution of fluorine for chlorine enhances the resistance of desflurane to
biodegradation. In patients given 3.1 MAC-hrs of anesthesia, or volunteers given 7.4
MAC-hrs, no measurable increase in serum inorganic fluoride is found [28]. Similarly,
urinary inorganic fluoride or organic fluoride changes little or none at all. Measurement
ofblood and urine does reveal trace amounts oftrifluoroacetate afteranesthesia with des-
flurane, but the amounts produced appear to be approximately one-tenth that produced
after anesthesia with isoflurane. Metabolism appears to remove 0.02% of the desflurane
that is taken up. The metabolism of isoflurane, heretofor the least metabolized of the
modem inhaled anesthetics, is ten times greater.
The minimal metabolism ofdesflurane suggests that it should have little orno toxici-
ty. Results ofstudies in patients and volunteers support this prediction [7]. No nephrotox-
icity or hepatotoxicity have been reported. Studies in animals subjected to prolonged
anesthesia and/or deep levels ofanesthesia, or anesthesia with concurrent stresses such as
enzyme induction and hypoxia, or anesthesia with desflurane repeated several times a
week overeight weeks, do notreveal evidence ofnephrotoxicity orhepatotoxicity.
The data from studies in humans cover a limited number of subjects. Because the
metabolism ofdesflurane produces trifluoroacetate, and because trifluoroacetate is impli-
cated in the hepatotoxicity of halothane via an allergic phenomenon, it is possible to
imagine thatdesflurane could produce hepatic injury in arare patient by a similar mecha-
nism. However, this possibility would appear to be vanishingly small. Isoflurane is
metabolized to an identical end-product but, if hepatic injury results from isoflurane's
metabolism, the incidence appears to be a minute fraction of that which occurs with
halothane. Given that isoflurane's metabolism is ten times thatofdesflurane, therisk with
desflurane mustbe still less or nonexistant.
Summary
The modem inhaled anesthetics constituted a remarkable advance over the smelly,
sometimes toxic, sometimes flammable compounds available to me in my residency. We
have yet to find the ideal inhaled anesthetic. The pungency ofdesflurane and the capacity
of desflurane to increase heart rate are not what we would wish in the ideal agent.
However, in terms of solubility and control over the maintenance of anesthesia and
recovery from anesthesia, in terms of resistance to biodegradation, desflurane comes
close to the ideal.
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